April 12, 2026

Crispr Therapeutics targets trillions in chronic disease market with AI and CRISPR

Demis Hassabis has articulated a vision for the future of medicine, advocating for a shift from “sickcare” to a focus on cures and prevention through AI and genetic editing technologies. He highlights how AI-Genomics tools like DeepMind’s AlphaGenome can decode non-coding DNA to identify specific mutations that cause diseases, while CRISPR Therapeutics is already generating revenue from therapies for blood disorders and is targeting broader markets, with the potential to transform the treatment landscape. Despite the promise, investor confidence remains low, as indicated by the relatively small market caps of key companies in the sector, reflecting a hesitance to embrace this revolutionary approach to healthcare.

r0ck3t23: r0ck3t23, or Dustin, is an X commentator translating AI and exponential tech transitions into accessible insights. In the news, he quotes and expands on Demis Hassabis’s vision of AI mapping genomic errors for CRISPR to delete diseases at the source. His bio emphasizes signaling the AI story amid linear human intuition.
AlphaGenome: AlphaGenome is Google DeepMind’s advanced AI model that analyzes long DNA sequences to predict functional impacts of genetic variants at base-pair resolution, including in non-coding regions. In the news, Hassabis highlights its ability to identify single mutations or cascades causing diseases for precise CRISPR interventions. It was published in Nature in early 2026 with expert reactions noting its leap in genomics.
Demis Hassabis: Demis Hassabis is the co-founder and CEO of Google DeepMind, a leading AI lab focused on scientific breakthroughs including protein structure prediction with AlphaFold. In the news, he describes shifting healthcare from ‘sickcare’ to prevention and cures by combining AI like AlphaGenome for pinpointing genetic mutations with CRISPR editing. He recently discussed accelerating science and medicine through AI.
Crispr Therapeutics: CRISPR Therapeutics is a biotechnology company developing gene-based medicines using the CRISPR/Cas9 platform to treat serious diseases. In the news, it is already generating revenue from approved cures for sickle cell disease and beta thalassemia while targeting larger markets like cardiovascular disease. Recent updates highlight its strategic priorities and CASGEVY gaining momentum entering 2026.
Intellia Therapeutics: Intellia Therapeutics is a clinical-stage biotech company advancing CRISPR-based therapies for genetic diseases, both in vivo and ex vivo. The news points to it as a key patent holder in gene editing despite investor skepticism on valuations. Recently, the FDA lifted a clinical hold on its Phase 3 trial for ATTR cardiomyopathy.

AI-Genomics Tool: DeepMind’s AlphaGenome decodes non-coding DNA to predict disease-causing mutations, enabling targeted gene edits.
CRISPR Revenue Shift: CRISPR Therapeutics reports momentum in approved therapies for blood disorders, focusing on broader disease cures.
Regulatory Clearance: FDA lifted clinical hold on Intellia Therapeutics’ Phase 3 trial targeting ATTR cardiomyopathy.

Sources